Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $41.16 USD
Change Today -2.38 / -5.47%
Volume 372.1K
RDUS On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

radius health inc (RDUS) Snapshot

Open
$43.45
Previous Close
$43.54
Day High
$44.07
Day Low
$41.10
52 Week High
02/13/15 - $51.22
52 Week Low
06/16/14 - $7.46
Market Cap
1.6B
Average Volume 10 Days
526.1K
EPS TTM
$-25.47
Shares Outstanding
37.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for RADIUS HEALTH INC (RDUS)

Related News

No related news articles were found.

radius health inc (RDUS) Related Businessweek News

No Related Businessweek News Found

radius health inc (RDUS) Details

Radius Health, Inc., a biopharmaceutical company, focuses on developing therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases in the United States. The company’s lead product comprises abaloparatide SC (BA058), a novel synthetic peptide analog of parathyroid hormone-related protein that is in Phase III clinical development for use in the reduction of fractures in postmenopausal osteoporosis; and Abaloparatide-TD, a line extension of abaloparatide-SC in the form of a transdermal patch that has completed Phase II clinical trial, which is used to increase bone mineral density. It is also developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer and other estrogen receptor mediated oncology applications, as well as in Phase II proof of concept study for the treatment of vasomotor symptoms; and RAD140, a nonsteroidal selective androgen receptor modulator for the treatment of breast cancer or other conditions. The company has collaborations and license agreements with Nordic Bioscience Clinical Development VII A/S; 3M; Ipsen Pharma SAS; Eisai Co. Ltd; and Lonza Group Ltd. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

25 Employees
Last Reported Date: 03/10/15
Founded in 2003

radius health inc (RDUS) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $450.0K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $346.2K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $300.9K
Chief Medical Officer
Total Annual Compensation: $287.6K
Chief Development Officer
Total Annual Compensation: $321.3K
Compensation as of Fiscal Year 2014.

radius health inc (RDUS) Key Developments

Radius Health, Inc. Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Radius Health, Inc. announced earnings results for the fourth quarter and full year ended December 31, 2014. For the three months ended December 31, 2014, Radius reported a net loss of $18.0 million, or $0.55 per share, as compared to a net loss of $12.5 million, or $44.87 per share for the three months ended December 31, 2013. The net loss per share calculation for the three months ended December 31, 2014 includes the impact of the conversion of Radius' convertible preferred stock into common stock upon the completion of its initial public offering in June 2014. The increase in net loss for the 2014 period as compared to the 2013 period was primarily due to an increase in general and administrative expenses, partially offset by a decrease in other income (expense), net. Loss from operations was $17,196,000 against $13,652,000 a year ago. For the twelve months ended December 31, 2014, Radius reported a net loss of $62.5 million, or $4.04 per share, as compared to a net loss of $60.7 million, or $203.91 per share for the twelve months ended December 31, 2013. The net loss per share calculation for the twelve months ended December 31, 2014 includes the impact of the conversion of Radius' convertible preferred stock into common stock upon the completion of its initial public offering in June 2014. The increase in net loss for the 2014 period was primarily due to a decrease in other income (expense), net and an increase in general and administrative expenses, partially offset by a decrease in research and development expenses. Loss from operations was $59,393,000 against $67,365,000 a year ago.

Radius Health, Inc. Presents at Merrill Lynch Smid Cap Conference 2015, Mar-18-2015 08:00 AM

Radius Health, Inc. Presents at Merrill Lynch Smid Cap Conference 2015, Mar-18-2015 08:00 AM. Venue: Four Seasons Hotel, 200 Boylston street, Boston, Massachusetts, United States. Speakers: Gary Hattersley, Chief Scientific Officer and Senior Vice President.

Radius Health, Inc. Announces Board Changes

Radius Health, Inc. announced the appointment of Tony Rosenberg to its board of directors. Tony Rosenberg will also be taking the role of chair of the strategy committee, replacing Dr. Morana Jovan, who resigned from the Board. In 2013, he was appointed as Corporate Head of M&A and Licensing. Most recently, Tony was responsible for the Portfolio Transformation transactions undertaken by Novartis. He previously held various general management and executive leadership positions, including roles in business development, strategic planning, and marketing and sales.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RDUS:US $41.16 USD -2.38

RDUS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
West Pharmaceutical Services Inc $60.21 USD +0.51
View Industry Companies
 

Industry Analysis

RDUS

Industry Average

Valuation RDUS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 22.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RADIUS HEALTH INC, please visit www.radiuspharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.